{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T23:55:40Z","timestamp":1769903740505,"version":"3.49.0"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81172860"],"award-info":[{"award-number":["81172860"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.cca.2015.02.007","type":"journal-article","created":{"date-parts":[[2015,2,11]],"date-time":"2015-02-11T02:19:01Z","timestamp":1423621141000},"page":"117-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Discovery of new biomarkers of idiopathic inflammatory myopathy"],"prefix":"10.1016","volume":"444","author":[{"given":"Xin","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinglin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guochun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2015.02.007_bb0005","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ncl.2014.04.007","article-title":"Idiopathic inflammatory myopathies","volume":"32","author":"Dimachkie","year":"2014","journal-title":"Neurol Clin"},{"key":"10.1016\/j.cca.2015.02.007_bb0010","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11926-013-0335-1","article-title":"Autoantibodies in polymyositis and dermatomyositis","volume":"15","author":"Ghirardello","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.cca.2015.02.007_bb0015","doi-asserted-by":"crossref","first-page":"909","DOI":"10.6061\/clinics\/2013(07)04","article-title":"Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis","volume":"68","author":"Cruellas","year":"2013","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.cca.2015.02.007_bb0020","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s11926-014-0446-3","article-title":"Strategies for evaluating idiopathic inflammatory myopathy disease susceptibility genes","volume":"16","author":"Rothwell","year":"2014","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.cca.2015.02.007_bb0025","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/BOR.0b013e3283315a22","article-title":"An update on the immunogenetics of idiopathic inflammatory myopathies: major histocompatibility complex and beyond","volume":"21","author":"Chinoy","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.cca.2015.02.007_bb0030","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/ar3327","article-title":"Recent advances in the immunogenetics of idiopathic inflammatory myopathy","volume":"13","author":"Chinoy","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cca.2015.02.007_bb0035","first-page":"S139","article-title":"Clinical and serological characterisation of the anti-MJ antibody in childhood myositis (abstract)","volume":"40","author":"Oddis","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"Suppl9","key":"10.1016\/j.cca.2015.02.007_bb0040","first-page":"S787","article-title":"Sera with autoantibodies to the MJ antigen react with NXP2 (abstract)","volume":"56","author":"Targoff","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2015.02.007_bb0045","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1242\/jcs.063586","article-title":"Two-step colocalization of MORC3 with PML nuclear bodies","volume":"123","author":"Mimura","year":"2010","journal-title":"J Cell Sci"},{"key":"10.1016\/j.cca.2015.02.007_bb0050","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/art.24547","article-title":"Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis","volume":"60","author":"Gunawardena","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2015.02.007_bb0055","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.3899\/jrheum.090461","article-title":"Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein","volume":"36","author":"Espada","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.cca.2015.02.007_bb0060","doi-asserted-by":"crossref","first-page":"R97","DOI":"10.1186\/ar3822","article-title":"Anti-MJ\/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis\/dermatomyositis","volume":"14","author":"Ceribelli","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cca.2015.02.007_bb0065","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2011-200697","article-title":"Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy","volume":"71","author":"Ichimura","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cca.2015.02.007_bb0070","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2015.02.007_bb0075","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.21023","article-title":"Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis","volume":"52","author":"Sato","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2015.02.007_bb0080","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/art.24621","article-title":"RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease","volume":"60","author":"Sato","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2015.02.007_bb0085","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/rheumatology\/keq153","article-title":"Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis","volume":"49","author":"Hoshino","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cca.2015.02.007_bb0090","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/rheumatology\/ker518","article-title":"The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM","volume":"51","author":"Koga","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cca.2015.02.007_bb0095","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/rheumatology\/keq149","article-title":"Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis","volume":"49","author":"Gono","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cca.2015.02.007_bb0100","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/acr.21985","article-title":"Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis","volume":"65","author":"Chen","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.cca.2015.02.007_bb0105","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/1471-2474-11-223","article-title":"Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis","volume":"11","author":"Kang","year":"2010","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.cca.2015.02.007_bb0110","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/acr.21992","article-title":"Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum","volume":"65","author":"Hall","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.cca.2015.02.007_bb0115","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","article-title":"The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study","volume":"65","author":"Fiorentino","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.cca.2015.02.007_bb0120","article-title":"Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease","author":"Narang","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.cca.2015.02.007_bb0125","doi-asserted-by":"crossref","first-page":"290797","DOI":"10.1155\/2014\/290797","article-title":"Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis","volume":"2014","author":"Labrador-Horrillo","year":"2014","journal-title":"J Immunol Res"},{"key":"10.1016\/j.cca.2015.02.007_bb0130","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jpeds.2010.11.033","article-title":"Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis","volume":"158","author":"Kobayashi","year":"2011","journal-title":"J Pediatr"},{"key":"10.1016\/j.cca.2015.02.007_bb0135","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1002\/art.37985","article-title":"Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis","volume":"65","author":"Shah","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2015.02.007_bb0140","doi-asserted-by":"crossref","first-page":"R138","DOI":"10.1186\/ar4600","article-title":"Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study","volume":"16","author":"Tansley","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cca.2015.02.007_bb0145","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1002\/art.22164","article-title":"A novel autoantibody to a 155-kd protein is associated with dermatomyositis","volume":"54","author":"Targoff","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2015.02.007_bb0150","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/rheumatology\/kel161","article-title":"Identification of a novel autoantibody reactive with 155 and 140kDa nuclear proteins in patients with dermatomyositis: an association with malignancy","volume":"46","author":"Kaji","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cca.2015.02.007_bb0155","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1136\/ard.2006.068502","article-title":"The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis","volume":"66","author":"Chinoy","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cca.2015.02.007_bb0160","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/MD.0b013e3181ca14ff","article-title":"Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy","volume":"89","author":"Trallero-Araguas","year":"2010","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cca.2015.02.007_bb0165","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/art.33379","article-title":"Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis","volume":"64","author":"Trallero-Araguas","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2015.02.007_bb0170","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/art.33403","article-title":"Myositis-specific anti-155\/140 autoantibodies target transcription intermediary factor 1 family proteins","volume":"64","author":"Fujimoto","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2015.02.007_bb0175","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/rheumatology\/kes073","article-title":"Clinical features of anti-TIF1-alpha antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-gamma or anti-Mi-2 autoantibodies","volume":"51","author":"Muro","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cca.2015.02.007_bb0180","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1186\/ar3802","article-title":"Autoantibodies to transcription intermediary factor TIF1beta associated with dermatomyositis","volume":"14","author":"Satoh","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"supp2","key":"10.1016\/j.cca.2015.02.007_bb0185","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/annrheumdis-2014-eular.2390","article-title":"Significance of relationship between anti-TIF1 autoantibodies profiles and cancer-associated myositis","volume":"73","author":"Lu","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cca.2015.02.007_bb0190","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/rheumatology\/kem359","article-title":"Clinical associations of autoantibodies to a p155\/140kDa doublet protein in juvenile dermatomyositis","volume":"47","author":"Gunawardena","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cca.2015.02.007_bb0195","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/MD.0b013e31829d08f9","article-title":"The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies","volume":"92","author":"Rider","year":"2013","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cca.2015.02.007_bb0200","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1002\/art.22862","article-title":"Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis","volume":"56","author":"Betteridge","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2015.02.007_bb0205","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1136\/ard.2008.097162","article-title":"Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis","volume":"68","author":"Betteridge","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cca.2015.02.007_bb0210","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jim.2012.07.019","article-title":"Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort","volume":"384","author":"Tarricone","year":"2012","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.cca.2015.02.007_bb0215","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3109\/08916934.2012.755958","article-title":"Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients","volume":"46","author":"Muro","year":"2013","journal-title":"Autoimmunity"},{"key":"10.1016\/j.cca.2015.02.007_bb0220","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/annrheumdis-2012-201736","article-title":"Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis: comparison with a UK Caucasian cohort","volume":"72","author":"Fujimoto","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cca.2015.02.007_bb0225","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2015.02.007_bb0230","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2015.02.007_bb0235","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/acr.20662","article-title":"Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.cca.2015.02.007_bb0240","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1002\/art.34673","article-title":"Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"64","author":"Werner","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2015.02.007_bb0245","doi-asserted-by":"crossref","first-page":"R39","DOI":"10.1186\/ar4468","article-title":"Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies","volume":"16","author":"Drouot","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cca.2015.02.007_bb0250","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MD.0000000000000028","article-title":"Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin","volume":"93","author":"Allenbach","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cca.2015.02.007_bb0255","doi-asserted-by":"crossref","first-page":"e20266","DOI":"10.1371\/journal.pone.0020266","article-title":"Autoantibodies against a 43 KDa muscle protein in inclusion body myositis","volume":"6","author":"Salajegheh","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2015.02.007_bb0260","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ana.23822","article-title":"Autoantibodies to cytosolic 5\u2032-nucleotidase 1A in inclusion body myositis","volume":"73","author":"Pluk","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cca.2015.02.007_bb0265","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.23840","article-title":"Cytosolic 5\u2032-nucleotidase 1A autoimmunity in sporadic inclusion body myositis","volume":"73","author":"Larman","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cca.2015.02.007_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.1995.tb32309.x","article-title":"Interleukin-6-type cytokines","volume":"762","author":"Sehgal","year":"1995","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.cca.2015.02.007_bb0275","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/art.1780400514","article-title":"Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies","volume":"40","author":"Lundberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2015.02.007_bb0280","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1002\/art.24936","article-title":"Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis","volume":"60","author":"Bilgic","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2015.02.007_bb0285","doi-asserted-by":"crossref","first-page":"717808","DOI":"10.1155\/2013\/717808","article-title":"Serum interleukin-6 expression level and its clinical significance in patients with dermatomyositis","volume":"2013","author":"Yang","year":"2013","journal-title":"Clin Dev Immunol"},{"issue":"12","key":"10.1016\/j.cca.2015.02.007_bb0290","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","article-title":"Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease","volume":"53","author":"Gono","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cca.2015.02.007_bb0295","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3109\/14397595.2013.844390","article-title":"Serum interleukin 6 levels as a useful prognostic predictor of clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease","volume":"24","author":"Nara","year":"2014","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.cca.2015.02.007_bb0300","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/intimm\/12.9.1329","article-title":"Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation","volume":"12","author":"De","year":"2000","journal-title":"Int Immunol"},{"key":"10.1016\/j.cca.2015.02.007_bb0305","doi-asserted-by":"crossref","first-page":"6593","DOI":"10.4049\/jimmunol.164.12.6593","article-title":"Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production","volume":"164","author":"Sugiura","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.cca.2015.02.007_bb0310","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0165-5728(03)00032-8","article-title":"Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis","volume":"137","author":"Chevrel","year":"2003","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.cca.2015.02.007_bb0315","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cyto.2009.02.013","article-title":"Th1 and Th17 balance in inflammatory myopathies: interaction with dendritic cells and possible link with response to high-dose immunoglobulins","volume":"46","author":"Tournadre","year":"2009","journal-title":"Cytokine"},{"key":"10.1016\/j.cca.2015.02.007_bb0320","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/03009742.2010.517215","article-title":"Interleukin-17 and interleukin-23 in patients with polymyositis and dermatomyositis","volume":"40","author":"Shen","year":"2011","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.cca.2015.02.007_bb0325","first-page":"428","article-title":"Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis","volume":"31","author":"Yuan","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.cca.2015.02.007_bb0330","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.autrev.2013.10.010","article-title":"Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases","volume":"13","author":"Antonelli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.cca.2015.02.007_bb0335","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/art.38676","article-title":"Correlation of CXCL10, tumor necrosis factor receptor type II, and galectin 9 with disease activity in juvenile dermatomyositis","volume":"66","author":"Bellutti","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2015.02.007_bb0340","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejcb.2011.09.011","article-title":"Inflammatory response in human skeletal muscle cells: CXCL10 as a potential therapeutic target","volume":"91","author":"Crescioli","year":"2012","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.cca.2015.02.007_bb0345","doi-asserted-by":"crossref","first-page":"R126","DOI":"10.1186\/ar4583","article-title":"Therapeutic effect of anti-C-X-C motif chemokine 10 (CXCL10) antibody on C protein-induced myositis mouse","volume":"16","author":"Kim","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cca.2015.02.007_bb0350","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.4049\/jimmunol.175.10.6987","article-title":"Inhibition of CX3CL1 (fractalkine) improves experimental autoimmune myositis in SJL\/J mice","volume":"175","author":"Suzuki","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.cca.2015.02.007_bb0355","doi-asserted-by":"crossref","first-page":"R48","DOI":"10.1186\/ar3761","article-title":"Serum level of soluble CX3CL1\/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activity","volume":"14","author":"Suzuki","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cca.2015.02.007_bb0360","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11926-011-0166-x","article-title":"Pathogenesis of dermatomyositis: role of cytokines and interferon","volume":"13","author":"Kao","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.cca.2015.02.007_bb0365","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nrrheum.2009.237","article-title":"Type I interferons: crucial participants in disease amplification in autoimmunity","volume":"6","author":"Hall","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.cca.2015.02.007_bb0370","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cca.2015.02.007_bb0375","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1212\/WNL.0b013e31821f440a","article-title":"Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies","volume":"76","author":"Cappelletti","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2015.02.007_bb0380","doi-asserted-by":"crossref","first-page":"e65362","DOI":"10.1371\/journal.pone.0065362","article-title":"Type 1 interferons inhibit myotube formation independently of upregulation of interferon-stimulated gene 15","volume":"8","author":"Franzi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2015.02.007_bb0385","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ana.21805","article-title":"Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy","volume":"67","author":"Salajegheh","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cca.2015.02.007_bb0390","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1136\/ard.2010.141051","article-title":"Serum levels of interferon alpha do not correlate with disease activity in patients with dermatomyositis\/polymyositis","volume":"70","author":"Krol","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cca.2015.02.007_bb0395","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/ard.2010.139949","article-title":"Interferon beta is associated with type 1 interferon-inducible gene expression in dermatomyositis","volume":"70","author":"Liao","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cca.2015.02.007_bb0400","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/08916930600622256","article-title":"Cytokines in idiopathic inflammatory myopathies","volume":"39","author":"Salomonsson","year":"2006","journal-title":"Autoimmunity"},{"key":"10.1016\/j.cca.2015.02.007_bb0405","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/BOR.0000000000000109","article-title":"Therapy of myositis: biological and physical","volume":"26","author":"Lundberg","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.cca.2015.02.007_bb0410","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.autrev.2011.06.007","article-title":"Therapy of polymyositis and dermatomyositis","volume":"11","author":"Marie","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.cca.2015.02.007_bb0415","first-page":"203","article-title":"Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma","volume":"18","author":"Kohno","year":"1988","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.cca.2015.02.007_bb0420","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1067\/mpd.2001.110324","article-title":"KL-6 is a potential marker for interstitial lung disease associated with juvenile dermatomyositis","volume":"138","author":"Kobayashi","year":"2001","journal-title":"J Pediatr"},{"key":"10.1016\/j.cca.2015.02.007_bb0425","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.rmed.2004.04.003","article-title":"Role of KL-6 in evaluating the disease severity of rheumatoid lung disease: comparison with HRCT","volume":"98","author":"Kinoshita","year":"2004","journal-title":"Respir Med"},{"key":"10.1016\/j.cca.2015.02.007_bb0430","first-page":"429","article-title":"Longitudinal analysis of serum KL-6 levels in patients with systemic sclerosis: association with the activity of pulmonary fibrosis","volume":"21","author":"Yanaba","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.cca.2015.02.007_bb0435","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1136\/ard.59.4.257","article-title":"Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis\/dermatomyositis","volume":"59","author":"Bandoh","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cca.2015.02.007_bb0440","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/rheumatology\/39.6.632","article-title":"Serum KL-6 in adult patients with polymyositis and dermatomyositis","volume":"39","author":"Kubo","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cca.2015.02.007_bb0445","first-page":"414","article-title":"Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato\/polymyositis","volume":"26","author":"Kumanovics","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.cca.2015.02.007_bb0450","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1365-2796.2011.02459.x","article-title":"KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis","volume":"271","author":"Fathi","year":"2012","journal-title":"J Intern Med"},{"key":"10.1016\/j.cca.2015.02.007_bb0455","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1136\/ard.2008.091405","article-title":"Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies","volume":"68","author":"Krystufkova","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cca.2015.02.007_bb0460","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2217\/bmm.13.124","article-title":"B-cell activating factor as a serological biomarker for polymyositis and dermatomyositis","volume":"8","author":"Peng","year":"2014","journal-title":"Biomark Med"},{"key":"10.1016\/j.cca.2015.02.007_bb0465","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3899\/jrheum.120555","article-title":"BAFF expression correlates with idiopathic inflammatory myopathy disease activity measures and autoantibodies","volume":"40","author":"Lopez De Padilla","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.cca.2015.02.007_bb0470","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1186\/s13075-014-0454-8","article-title":"Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52\/anti-Ro60 autoantibodies","volume":"16","author":"Kry","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cca.2015.02.007_bb0475","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/rheumatology\/kep248","article-title":"HLA-DPB1 associations differ between DRB1*03 positive anti-Jo-1 and anti-PM-Scl antibody positive idiopathic inflammatory myopathy","volume":"48","author":"Chinoy","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cca.2015.02.007_bb0480","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/art.22205","article-title":"HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies","volume":"54","author":"O'Hanlon","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2015.02.007_bb0485","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1002\/art.34657","article-title":"Brief report: Association of HLA-DRB1*0101\/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population","volume":"64","author":"Gono","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2015.02.007_bb0490","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1046\/j.1523-1747.2002.19608.x","article-title":"Mannose binding lectin (MBL) polymorphisms associated with low MBL production in patients with dermatomyositis","volume":"119","author":"Werth","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.cca.2015.02.007_bb0495","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/08916930701464897","article-title":"Protein tyrosine phosphatase PTPN22 in human autoimmunity","volume":"40","author":"Vang","year":"2007","journal-title":"Autoimmunity"},{"key":"10.1016\/j.cca.2015.02.007_bb0500","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.4049\/jimmunol.179.7.4704","article-title":"Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes","volume":"179","author":"Rieck","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.cca.2015.02.007_bb0505","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1002\/art.24039","article-title":"Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis","volume":"58","author":"Mamyrova","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2015.02.007_bb0510","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1002\/art.38137","article-title":"Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders","volume":"65","author":"Miller","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2015.02.007_bb0515","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1136\/annrheumdis-2014-205440","article-title":"Genotyping of immune-related genetic variants identifies TYK2 as a novel associated locus for idiopathic inflammatory myopathies","volume":"73","author":"Jani","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cca.2015.02.007_bb0520","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0092-8674(93)90529-Y","article-title":"The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14","volume":"75","author":"Lee","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.cca.2015.02.007_bb0525","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.cca.2015.02.007_bb0530","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jaut.2009.02.012","article-title":"MicroRNA in autoimmunity and autoimmune diseases","volume":"32","author":"Pauley","year":"2009","journal-title":"J Autoimmun"},{"key":"10.1016\/j.cca.2015.02.007_bb0535","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1186\/ar2493","article-title":"Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients","volume":"10","author":"Pauley","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cca.2015.02.007_bb0540","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1177\/0961203310389841","article-title":"Serum and urinary free microRNA level in patients with systemic lupus erythematosus","volume":"20","author":"Wang","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.cca.2015.02.007_bb0545","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1038\/emm.2013.71","article-title":"MicroRNAs: their involvement in fibrosis pathogenesis and use as diagnostic biomarkers in scleroderma","volume":"45","author":"Zhu","year":"2013","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.cca.2015.02.007_bb0550","doi-asserted-by":"crossref","first-page":"17016","DOI":"10.1073\/pnas.0708115104","article-title":"Distinctive patterns of microRNA expression in primary muscular disorders","volume":"104","author":"Eisenberg","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cca.2015.02.007_bb0555","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1002\/art.34606","article-title":"Increased expression of vascular cell adhesion molecule 1 in muscle biopsy samples from juvenile dermatomyositis patients with short duration of untreated disease is regulated by miR-126","volume":"64","author":"Kim","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.cca.2015.02.007_bb0560","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/art.38292","article-title":"Inhibition of myogenic MicroRNAs-1, 133, and 206 by inflammatory cytokines links inflammation and muscle degeneration in adult inflammatory myopathies","volume":"66","author":"Georgantas","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2015.02.007_bb0565","doi-asserted-by":"crossref","first-page":"345347","DOI":"10.1155\/2013\/345347","article-title":"Correlation between the frequency of Th17 cell and the expression of microRNA-206 in patients with dermatomyositis","volume":"2013","author":"Tang","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.cca.2015.02.007_bb0570","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2340\/00015555-1459","article-title":"Decreased miR-7 expression in the skin and sera of patients with dermatomyositis","volume":"93","author":"Oshikawa","year":"2013","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.cca.2015.02.007_bb0575","first-page":"161","article-title":"Serum miR-21 levels in patients with dermatomyositis","volume":"31","author":"Shimada","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.cca.2015.02.007_bb0580","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/jclinpath-2011-200138","article-title":"Validity of internal expression of the major histocompatibility complex class I in the diagnosis of inflammatory myopathies","volume":"65","author":"Salaroli","year":"2012","journal-title":"J Clin Pathol"},{"issue":"12","key":"10.1016\/j.cca.2015.02.007_bb0585","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.nmd.2014.06.436","article-title":"An analysis of the sensitivity and specificity of MHC-I and MHC-II immunohistochemical staining in muscle biopsies for the diagnosis of inflammatory myopathies","volume":"24","author":"Rodriguez","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.cca.2015.02.007_bb0590","doi-asserted-by":"crossref","first-page":"9209","DOI":"10.1073\/pnas.97.16.9209","article-title":"Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies","volume":"97","author":"Nagaraju","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cca.2015.02.007_bb0595","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","article-title":"Pathogen recognition and innate immunity","volume":"124","author":"Akira","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.cca.2015.02.007_bb0600","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10067-009-1316-7","article-title":"Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis","volume":"29","author":"Kim","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.cca.2015.02.007_bb0605","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/NEN.0b013e31826bf7f3","article-title":"Toll-like receptors promote inflammation in idiopathic inflammatory myopathies","volume":"71","author":"Brunn","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.cca.2015.02.007_bb0610","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1002\/art.27465","article-title":"Expression of Toll-like receptor 3 and Toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines","volume":"62","author":"Tournadre","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2015.02.007_bb0615","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/art.33350","article-title":"Immature muscle precursors are a source of interferon-beta in myositis: role of Toll-like receptor 3 activation and contribution to HLA class I up-regulation","volume":"64","author":"Tournadre","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cca.2015.02.007_bb0620","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1136\/annrheumdis-2012-202207","article-title":"TLR4 as receptor for HMGB1 induced muscle dysfunction in myositis","volume":"72","author":"Zong","year":"2013","journal-title":"Ann Rheum Dis"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898115000704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898115000704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T20:02:00Z","timestamp":1762113720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898115000704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":124,"alternative-id":["S0009898115000704"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2015.02.007","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of new biomarkers of idiopathic inflammatory myopathy","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2015.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}